Cargando…
Vedolizumab as a Potential Culprit in the Development of Ovarian Teratoma?
Vedolizumab is a new humanized monoclonal antibody that has been reserved for those with moderate-to-severe Crohn's disease and ulcerative colitis who have failed immunomodulator and TNF-α antagonist therapy, and for those who have an increased risk for developing progressive multifocal leukoen...
Autores principales: | Trieu, Judy A., Bilal, Mohammad, Luthra, Gurinder |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5875294/ https://www.ncbi.nlm.nih.gov/pubmed/29606936 http://dx.doi.org/10.1159/000484199 |
Ejemplares similares
-
Acute Chest Pain as an Infusion Reaction to Vedolizumab
por: Levartovsky, Asaf, et al.
Publicado: (2022) -
Vedolizumab Treatment for Ulcerative Colitis in an Elderly Multimorbid Patient with Hemophilia A
por: Schäffler, Holger, et al.
Publicado: (2017) -
A Novel Culprit in a Patient with Budd-Chiari Syndrome
por: Polman, Jeremy, et al.
Publicado: (2021) -
Fenofibrate-Induced Lichenoid Drug Eruption: A Rare Culprit
por: Mohammed, Fayeza, et al.
Publicado: (2017) -
Possible Efficacy of Vedolizumab, an Anti-α4β7 Integrin Antibody, in Palmoplantar Pustulosis
por: Terui, Hitoshi, et al.
Publicado: (2023)